Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response
Background Bispecific T-cell engagers (BiTEs) are recombinant bispecific proteins designed to stimulate polyclonal T-cell immunity. In recent years, B7H3, a pan-cancer antigen, has been considered a promising target for future immunotherapy. However, the B7H3-targeting BiTE faces the challenge of sy...
Saved in:
| Main Authors: | Ying Liu, Haoran Zhu, Wanrong Zhang, Guangzuo Luo, Qingguo Guo, Ruoyue Fan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/11/e009901.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas
Published: (2021-06-01) -
Mitochondrial metabolic reprogramming of macrophages and T cells enhances CD47 antibody-engineered oncolytic virus antitumor immunity
by: Ping Cheng, et al.
Published: (2024-12-01) -
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer
by: Solange R. Paredes-Moscosso, et al.
Published: (2024-12-01) -
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication
by: Eric Bartee, et al.
Published: (2020-05-01) -
CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
by: Yi Zhang, et al.
Published: (2020-05-01)